Pharmaceutical Executive January 13, 2026
Key Takeaways
- Regeneron’s strategy focuses on a broad pipeline across six therapeutic areas, with significant near-term data readouts expected to drive growth.
- The company anticipates 2026 as a pivotal year with multiple regulatory filings, clinical milestones, and new product launches.
- Regeneron’s platform-driven approach has resulted in 14 internally discovered approvals over the past 15 years.
- Key initiatives include late-stage programs in oncology, obesity, complement-mediated diseases, anticoagulation, and immunology.
- Schleifer highlighted Regeneron’s commitment to R&D investment and patient-centered innovation, with significant capital allocated for 2026.
Regeneron CEO Len Schleifer highlighted the company’s science-driven platform approach, strong 2025 commercial performance, and a robust pipeline across multiple therapeutic areas poised for regulatory filings, clinical milestones, and new product launches.
Regeneron CEO...
Today's Sponsors
Today's Sponsor